UK Tory Party's commitment to R&D tax credits welcomed by BIA

16 March 2010

On March 9, Sir James Dyson published his 'Ingenious Britain' report on how to make the UK the leading high tech exporter in Europe. The report was commissioned by Britain's Conservative Party, which welcomed Sir James' conclusions.

The trade group the BioIndustry Association (BIA) said it is delighted that Sir James has listened to calls from the life sciences sector and has recommended that the Conservative party retains R&D tax credits if they should win the election. Sir James' report proposes that R&D tax credits be refocused on high tech companies, small businesses and new start ups and that they should be boosted to 200 per cent when public finances allow.

The BIA added that it is further encouraged by Shadow Science and Innovation Minister, Adam Afriyie's comments later that day, at the third Science Debate, that the Conservatives are now committed to retaining R&D tax credits. He said that there was a need to refine and refocus them, but that there was a need to fix the economy before those issues can be addressed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology